Pinnacle Medicines Raises $89 Million Series B to Advance Oral Peptide Therapeutics into Clinical Trials
核心洞察
Pinnacle Medicines (搜索) closed an oversubscribed $89 million Series B financing co-led by LAV (搜索) and Foresite Capital (搜索) to advance its oral peptide therapeutics pipeline into clinical trials.
The company has raised $134 million to date and is developing oral peptide medicines designed to deliver biologic-level safety and efficacy with oral dosing convenience.
Proceeds will support advancement of lead programs through clinical proof of concept, focusing initially on immunology and cardiometabolic diseases.
Pinnacle Medicines (搜索), a biotechnology company pioneering oral peptide therapeutics, announced the closing of an oversubscribed $89 million Series B financing round to advance its pipeline into clinical trials. The round was co-led by LAV (搜索) and Foresite Capital (搜索), with participation from Quan Capital (搜索), Hankang Capital (搜索), RA Capital Management (搜索), Logos Capital (搜索), and existing investors including OrbiMed (搜索).
The company has now raised $134 million to date following incubation by OrbiMed (搜索) and other healthcare specialist investors. Proceeds from the financing will support the advancement of Pinnacle's lead programs through clinical proof of concept, with an initial focus on immunology and cardiometabolic diseases, while further expanding the company's proprietary peptide discovery platform and research and development capabilities.
Transformative Oral Peptide Platform
Pinnacle Medicines (搜索) is developing a new generation of oral peptide medicines designed to deliver biologic-level safety and efficacy with the convenience of oral dosing. The company's approach aims to overcome traditional delivery challenges associated with injectable biologics by unlocking the broader therapeutic potential of peptides across chronic disease areas.
"This financing marks an important milestone for Pinnacle Medicines (搜索) and reflects strong conviction in the transformative potential of oral peptide therapeutics," said Jonathan Wang, Chief Executive Officer of Pinnacle Medicines. "At Pinnacle, we are building a platform designed to unlock the full therapeutic potential of peptides through oral delivery. With this strong group of investors, we are now focused on translating that vision into clinical proof of concept and delivering transformative medicines for patients."
AI-Driven Discovery Platform
The company has built a proprietary platform that integrates artificial intelligence with physics-based simulations and advanced peptide chemistry to rationally design and optimize therapeutic candidates. This differentiated discovery approach positions the company to advance potential first- and best-in-class oral peptide programs targeting validated pathways.
Chengzao Sun, Ph.D., Chief Scientific Officer and Co-Founder, explained: "We have assembled an experienced peptide drug discovery and development team spanning all key disciplines and built a proprietary platform that integrates emerging AI technologies with physics-based simulations to rationally design and optimize peptide therapeutics. The rapid progression of our pipeline reflects the strength of this approach and positions us to advance a new generation of oral peptide medicines for chronic diseases."
Strong Investor Confidence
The oversubscribed financing round reflects strong investor conviction in the company's approach and potential market impact. Cindy Xiong, Partner at Foresite Capital (搜索), noted: "We are very excited about the future of oral peptide therapeutics, and Pinnacle Medicines (搜索) is emerging as a leader in this field. The team brings deep experience in peptide drug development and has demonstrated a remarkable ability to rapidly build both a differentiated discovery platform and a promising first-in-class pipeline."
David Wang, M.D., Ph.D., Partner and Senior Managing Director at OrbiMed (搜索), added: "We have supported Pinnacle Medicines (搜索) since inception and have been impressed by the team's scientific vision and execution. Oral peptide therapeutics have the potential to reshape treatment paradigms across multiple disease areas, and we are excited to continue supporting the company as it advances its pipeline toward clinical proof of concept."
The company is now positioned to advance its pipeline toward clinical-stage development, with investors highlighting the rapid progress in building both the discovery platform and therapeutic candidates targeting chronic diseases in immunology and cardiometabolic areas.